Journal of Assisted Reproduction and Genetics

, Volume 30, Issue 2, pp 233–238 | Cite as

The clinical ramifications of polycystic ovarian morphology in oocyte donors

  • M. Cho
  • G. Ambartsumyan
  • H. Danzer
  • K. Brennan
  • M. Surrey
Gonadal Physiology and Disease



To determine the relationship between Polycystic Ovary (PCO) morphology and In Vitro Fertilization (IVF) outcome in oocyte donation cycles.


Cross sectional study


Private IVF clinic


164 consecutive ovum donors and their recipients were reviewed, 149 were included in the study where 113 patients had normal ovarian morphology and 36 patients had PCO morphology.


All donors underwent ovarian stimulation in conjunction with GnRH agonist or antagonist in standard fashion.

Main Outcome Measures

Baseline donor characteristics were recorded, as well as details of IVF stimulation and embryo data. Recipient data on pregnancy and miscarriage were also collected.


Patients with PCO ovaries had significantly higher peak estradiol levels and required less gonadotropins during IVF stimulation. In addition, the baseline characteristics between donor groups did not differ except for ovarian morphology. The number of oocytes retrieved and indicators of embryo quality did not differ between the two groups, and there was no significant difference between pregnancy and miscarriage rates in the recipients.


Oocyte donors with PCO morphology have equivalent pregnancy rates and do not need to be excluded as potential donors.


Polycystic ovary morphology Polycystic ovary syndrome Oocyte donation 


  1. 1.
    Aboulghar MA, Mansour RT, Serour GI, Ramzy AM, Amin YM. Oocyte quality in patients with severe ovarian hyperstimulation syndrome. Fertility and sterility. 1997;68(6):1017–21.PubMedCrossRefGoogle Scholar
  2. 2.
    Adams JM, Taylor AE, Crowley Jr WF, Hall JE. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome. The Journal of clinical endocrinology and metabolism. 2004;89(9):4343–50.PubMedCrossRefGoogle Scholar
  3. 3.
    Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. The Journal of clinical endocrinology and metabolism. 2006;91(11):4237–45.PubMedCrossRefGoogle Scholar
  4. 4.
    Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: The complete task force report. Fertility and sterility. 2009;91(2):456–88.PubMedCrossRefGoogle Scholar
  5. 5.
    Carmina E, Wong L, Chang L, Paulson RJ, Sauer MV, Stanczyk FZ, Lobo RA. Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound. Human reproduction (Oxford, England). 1997;12(5):905–9.CrossRefGoogle Scholar
  6. 6.
    Cenk Sayin N, Gucer F, Balkanli-Kaplan P, Ali Yuce M, Yardim T. Insulin resistance and lipid profile in women with polycystic appearing ovaries: implications with regard to polycystic ovary syndrome. Gynecol Endocrinol. 2003;17(5):387–96.PubMedCrossRefGoogle Scholar
  7. 7.
    Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, Pigny P, Duhamel A, Catteau-Jonard S. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod. 2011;26(11):3123–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Dor J, Shulman A, Levran D, Ben-Rafael Z, Rudak E, Mashiach S. The treatment of patients with polycystic ovarian syndrome by in-vitro fertilization and embryo transfer: a comparison of results with those of patients with tubal infertility. Human reproduction (Oxford, England). 1990;5(7):816–8.Google Scholar
  9. 9.
    Dunaif A (1992) Polycystic ovary syndrome. Current issues in endocrinology and metabolism. Blackwell Scientific Publications; Distributors, USA and Canada, Mosby-Year Book, Boston, St. Louis, Mo.Google Scholar
  10. 10.
    Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine reviews. 1997;18(6):774–800.PubMedCrossRefGoogle Scholar
  11. 11.
    Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertility and sterility. 2008;89(1):84–91.PubMedCrossRefGoogle Scholar
  12. 12.
    Esmailzadeh S, Faramarzi M, Jorsarai G. Comparison of in vitro fertilization outcome in women with and without sonographic evidence of polycystic ovarian morphology. European journal of obstetrics, gynecology, and reproductive biology. 2005;121(1):67–70.PubMedCrossRefGoogle Scholar
  13. 13.
    Haning Jr RV, Austin CW, Carlson IH, Kuzma DL, Shapiro SS, Zweibel WJ. Plasma estradiol is superior to ultrasound and urinary estriol glucuronide as a predictor of ovarian hyperstimulation during induction of ovulation with menotropins. Fertility and sterility. 1983;40(1):31–6.PubMedGoogle Scholar
  14. 14.
    Homburg R, Levy T, Berkovitz D, Farchi J, Feldberg D, Ashkenazi J, Ben-Rafael Z. Gonadotropin-releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovarian syndrome. Fertility and sterility. 1993;59(3):527–31.PubMedGoogle Scholar
  15. 15.
    Howles CM, Macnamee MC, Edwards RG, Goswamy R, Steptoe PC. Effect of high tonic levels of luteinising hormone on outcome of in-vitro fertilisation. Lancet. 1986;2(8505):521–2.PubMedCrossRefGoogle Scholar
  16. 16.
    Legro RS. Pregnancy considerations in women with polycystic ovary syndrome. Clinical obstetrics and gynecology. 2007;50(1):295–304.PubMedCrossRefGoogle Scholar
  17. 17.
    Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Giudice LC, Leppert PC, Myers ER. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. The New England journal of medicine. 2007;356(6):551–66.PubMedCrossRefGoogle Scholar
  18. 18.
    PCOS. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Human reproduction (Oxford, England). 2004;19(1):41–7.CrossRefGoogle Scholar
  19. 19.
    Sagle M, Bishop K, Ridley N, Alexander FM, Michel M, Bonney RC, Beard RW, Franks S. Recurrent early miscarriage and polycystic ovaries. BMJ. 1988;297(6655):1027–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Swanton A, Lighten A, Granne I, McVeigh E, Lavery S, Trew G, Talmor A, Raine-Fenning N, Jayaprakasan K, Child T. Do women with ovaries of polycystic morphology without any other features of PCOS benefit from short-term metformin co-treatment during IVF? A double-blind, placebo-controlled, randomized trial. Human reproduction (Oxford, England). 2011;26(8):2178–84.CrossRefGoogle Scholar
  21. 21.
    Swanton A, Storey L, McVeigh E, Child T. IVF outcome in women with PCOS, PCO and normal ovarian morphology. European journal of obstetrics, gynecology, and reproductive biology. 2009;149(1):68–71.PubMedCrossRefGoogle Scholar
  22. 22.
    Tso LO, Costello MF, Albuquerque LE, Andriolo RB, Freitas V. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane database of systematic reviews (Online). 2009;2:CD006105.Google Scholar
  23. 23.
    Van Der Meer M, Hompes PG, De Boer JA, Schats R, Schoemaker J. Cohort size rather than follicle-stimulating hormone threshold level determines ovarian sensitivity in polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83(2):423–6.CrossRefGoogle Scholar
  24. 24.
    Wong IL, Morris RS, Lobo RA, Paulson RJ, Sauer MV. Isolated polycystic morphology in ovum donors predicts response to ovarian stimulation. Human reproduction (Oxford, England). 1995;10(3):524–8.Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • M. Cho
    • 1
    • 2
  • G. Ambartsumyan
    • 1
  • H. Danzer
    • 3
  • K. Brennan
    • 1
  • M. Surrey
    • 3
  1. 1.Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and GynecologyUniversity of CaliforniaLos AngelesUSA
  2. 2.Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and GynecologyCedars Sinai Medical CenterLos AngelesUSA
  3. 3.Southern California Reproductive CenterBeverly HillsUSA

Personalised recommendations